ACC.23: Bempedoic Acid Improves Outcomes in Statin-Intolerant Patients

Drug lowers LDL cholesterol and reduces risk of serious cardiovascular outcomes in large study

The cholesterol-lowering drug bempedoic acid reduced the combined rate of major adverse cardiovascular events by 13%, meeting its primary endpoint in a large study of patients with high cholesterol who were unable to tolerate statins, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.

Elevated low-density lipoprotein (LDL) cholesterol in the blood can lead to blocked arteries and raise the risk of a heart attack, stroke and other forms of heart disease. Statins are the standard first-line treatment for lowering cholesterol and reducing the risk of heart disease. Bempedoic acid affects the same biological pathway that statins target but is not activated until it reaches the liver. This limits the drug’s effects on muscle, the brain and other tissues or organs and explains why it does not have the same side effects reported with statins. It is approved by the U.S. Food and Drug Administration as an additional treatment to help lower cholesterol in patients with certain conditions who have high cholesterol despite receiving maximally tolerated statin therapy.

The trial, called CLEAR Outcomes, is the first to assess whether bempedoic acid could reduce cardiovascular outcomes. It showed the drug was associated with significant reductions in the trial’s primary endpoint, a composite of cardiovascular death, heart attack, stroke or coronary revascularization (a procedure to open blocked arteries). An analysis of different types of cardiac events found bempedoic acid led to a 23% reduction in heart attacks and a 19% reduction in coronary revascularizations, both of which were statistically significant. These benefits were seen in people who had previously experienced a cardiac event, as well as those who had not.

“We’re very pleased with the results,” said Steven E. Nissen, MD, chief academic officer of the Heart Vascular & Thoracic Institute at Cleveland Clinic and chair of the study. “People who couldn’t tolerate a statin did tolerate bempedoic acid and had a very good outcome. We are glad that we were able to demonstrate this level of efficacy on the outcomes that really matter to patients.”

The study enrolled over 14,000 statin-intolerant patients between December 2016 and August 2019 at over 1,200 sites in 32 countries. To participate, patients and their clinicians were required to acknowledge in writing their awareness of the benefits of statins and confirm the patient was unable to tolerate statin therapy. All participants had LDL levels of 100 mg/dL or higher at baseline and either a previous cardiac event or other risk factors for heart disease. On average, patients were 65 years old, nearly half were women (48%) and about 70% had experienced a previous cardiac event. Participants were randomly assigned to take 180 mg of bempedoic acid or a placebo daily and were followed for over three years, on average.

The combined rate of cardiovascular death, heart attack, stroke or coronary revascularization occurred in 11.7% of participants taking bempedoic acid and 13.3% of those taking a placebo. There was no significant difference in rates of death between the two study arms.

Those receiving bempedoic acid saw their LDL cholesterol levels drop by about 20%-25% on average over the course of the study. Participants taking a placebo also saw a modest reduction in LDL cholesterol (up to 10% on average), which likely reflects closer monitoring and the addition of other cholesterol-lowering agents as part of their background therapy, according to researchers.

Participants taking bempedoic acid experienced higher rates of several adverse events than those taking a placebo, including renal impairment, gout and gallstones, as well as elevated hepatic enzymes, likely due to the drug’s activity in the liver. However, these side effects did not lead to a higher rate of drug discontinuation.

Researchers said that the 20%-25% reduction in LDL cholesterol reported for bempedoic acid is less of an impact than the 40%-50% reductions typically achieved with statins, a finding in line with previous studies indicating that bempedoic acid is not as effective at lowering cholesterol as statins or other therapies such as PCSK9 inhibitors. However, the study shows that this degree of change can still make a difference in the overall risk of cardiac events for patients who cannot tolerate statins, Nissen said.

“Statins are the cornerstone of risk reduction in patients with elevated LDL cholesterol,” he said. “Most people can take statins, but some cannot. This is the first study that directly addressed the problem of statin-intolerant patients. We achieved what we hoped we would get—a very positive result in a population of people who just could not tolerate statins.”

The study was funded by Esperion Therapeutics, developer of bempedoic acid.

It was simultaneously published online in the New England Journal of Medicine at the time of presentation.

Nissen will be available to the media in a press conference on Saturday, March 4, at 10:45 a.m. CT / 16:45 UTC in the Rivergate Room.

Nissen will present the study, “Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk,” on Saturday, March 4, at 9:30 a.m. CT / 15:30 UTC in the Great Hall.

ACC.23/WCC will take place March 4-6, 2023, in New Orleans, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC23/#WCCardio for the latest news from the meeting.

The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at ACC.org.